Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2018-12-12
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of everolimus when given
together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has come
back (relapsed) or is not responding to treatment (refractory). Everolimus may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Brentuximab
vedotin may interfere with the ability of cancer cells to grow and spread by binding to a
protein on the surface of cancer cells and then releasing a cancer-killing substance to them.
Giving everolimus together with brentuximab vedotin may be a better treatment for Hodgkin
lymphoma.